GET DAILY SIGNALSNyxoah SA (NYXH) Reports +365% Revenue Growth in Q3 2026 Despite Trimmed Guidance
Key Takeaways
- Global net revenue reached €9.2 million in the third quarter of 2026, up 365% year over year and 19% sequentially, driven by U.S. net revenue of €6.7 million.
- Gross margin improved to 63.1% from 60.5% a year earlier, while the operating loss narrowed to €21.9 million from €24.4 million.
- Management lowered full-year 2026 revenue guidance to €33 million–€35 million from a prior range of €36 million–€40 million.
- U.S. commercial momentum continued, with 80 new surgeons trained and 53 new accounts activated during the quarter.
- The company submitted a premarket approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) to expand the Genio system's indication to patients with complete concentric collapse.
Why These Results Matter for Investors
Nyxoah SA is a Belgian medical technology company commercializing the Genio system, a bilateral hypoglossal nerve stimulation therapy for obstructive sleep apnea, a condition tied to cardiovascular risks. The third quarter of 2026 marks a key checkpoint in the U.S. commercial launch that followed FDA approval in August 2025. I am watching closely to see how quickly the U.S. ramp scales, whether reimbursement coverage broadens, and if clinical milestones expand the addressable patient base. These results indicate whether Nyxoah can turn regulatory success into sustained revenue growth while reducing losses in a competitive market.
Q3 Financial Performance
For the third quarter ended September 30, 2026, NYXH reported global net revenue of €9.2 million, a 365% increase from €2.0 million in the prior-year period and up 19% sequentially. U.S. net revenue was €6.7 million, up 29% from the second quarter, while international revenue rose 42% year over year to €2.5 million. Gross margin expanded to 63.1% from 60.5% a year earlier as costs were spread over higher device volumes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The total operating loss narrowed to €21.9 million from €24.4 million, and the net loss improved to €17.8 million from €23.6 million. Loss per share was €0.177, compared with €0.630 in the third quarter of 2025. Cash, cash equivalents, and financial assets totaled €77.1 million at quarter-end, down from €97.8 million at June 30, 2026.
On guidance, management trimmed its full-year 2026 revenue outlook to €33 million–€35 million from €36 million–€40 million, while maintaining a full-year gross margin expectation of 60%–62%. The revision had been signaled in an October 19 pre-announcement and reflected a U.S. ramp tracking a more typical adoption curve for new medical technology.
Market Reaction and Clinical Progress
Because the company pre-announced preliminary third-quarter revenue and the guidance cut on October 19, much of the market's reaction was already priced in ahead of the November 5 final results. Sentiment heading into the report balanced accelerating U.S. revenue growth against the reduced full-year outlook. The clinical news was a notable positive: the ACCCESS U.S. pivotal study met its efficacy and safety endpoints in complete concentric collapse patients, with a 12-month Apnea-Hypopnea Index responder rate of 77.2% and zero device- or procedure-related serious adverse events. This supported a PMA supplement to broaden the U.S. indication, potentially expanding the addressable market beyond patients currently contraindicated for available unilateral stimulation options.
Forward Outlook and Factors to Monitor
Investors should watch several catalysts in the coming quarters. The first is the pace of U.S. utilization: Nyxoah reported 342 surgeons trained, 233 active accounts, and 447 patients under prior authorization entering the fourth quarter. Converting that pipeline into implants will be central to meeting the revised revenue target. Reimbursement is another key variable. The Centers for Medicare & Medicaid Services published its 2027 final rule, raising hospital outpatient reimbursement for the Genio procedure from $31,526 to $35,072 and ambulatory surgical center reimbursement from $27,563 to $31,283. These increases strengthen the procedure's economic appeal to facilities. Regulatory progress also warrants attention. An FDA decision on the PMA supplement for complete concentric collapse patients could meaningfully widen the treatable population. Finally, cost discipline remains important as the company shifts spending from research and development toward commercial infrastructure while seeking to reduce cash burn quarter over quarter.
Enhancing Analysis with AI Tools
From what I see, Tickeron’s AI Screener helps surface relevant comparisons in the medical technology space quickly. I use it to scan for similar names and technical signals that complement fundamental reviews like this one, keeping the research process efficient without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NYXH in -2.35% downward trend, falling for three consecutive days on November 04, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NYXH declined for three days, in 270 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NYXH as a result. In 85 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Aroon Indicator for NYXH entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 70 cases where NYXH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for NYXH just turned positive on November 03, 2026. Looking at past instances where NYXH's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
Following a +5.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where NYXH advanced for three days, in 143 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
NYXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.994) is normal, around the industry mean (4.338). P/E Ratio (-0.370) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.746) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. NYXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NYXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement